Testing AK127 plus AK104 for advanced cancers
Part of Cancer clinical trials.
This Phase 1 study tests the safety and early anti-cancer activity of AK127 given together with AK104 in people with advanced solid tumors. You may be considered if standard treatments have already been tried or aren’t suitable for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old and able to give written informed consent.
- Your cancer must be advanced, recurrent, or metastatic, confirmed by lab tests (tumor tissue or cells).
- Your body’s overall function should be good (ECOG performance status 0 or 1) and you should have at least 3 months expected survival.
- You must have at least one measurable tumor spot that can be measured again over time; brain metastases cannot be used as the measuring target.
- You must have blood work/organ function that the study considers “good enough” for treatment (your clinicians will check this).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called AK137, which is a type of 'bispecific antibody' that targets two proteins (CD73 and LAG-3) to help your own immune system fight the cancer. It may be an option if your cancer has stopped responding to standard treatments.
This trial tests AK104 (an antibody medicine) given with standard chemotherapy as the first treatment for advanced pancreatic ductal cancer. It aims to see whether this combination works better and is safe for people with cancer that has spread or is advanced.
This early-stage study tests a combination of two study medicines (AK119 plus AK112) in people with advanced solid tumors that have grown or didn’t respond to standard treatment. It may help shrink tumors or improve how long people can stay on treatment by blocking cancer-related pathways.
This trial tests a new drug called AK138D1, either by itself or combined with another drug (ivonescimab), for people with advanced breast cancer. The goal is to see if the treatment can shrink tumors or slow the cancer's growth.
This Phase 1/2 trial tests a combination of two immune-targeting drugs (AK109 and AK104) in people with advanced solid tumors that can’t be treated with standard options, or where standard treatment didn’t work or wasn’t tolerated. It aims to find safe dosing and whether the treatment can shrink tumors or control the disease.
This study tests a new experimental drug called AK-1286 for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if the drug is safe and may help shrink tumors.
Hear when a new Advanced Malignant Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.